ArticleJAAD case reports2026

New-onset vitiligo following proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab: A possible immune-mediated adverse effect.

Carlos A Umaña Mejia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.